Feb 12 (Reuters) - Abbvie ABBV.N:
ABBVIE AND XILIO THERAPEUTICS ANNOUNCE COLLABORATION AND OPTION AGREEMENT TO DEVELOP NOVEL TUMOR-ACTIVATED IMMUNOTHERAPIES
ABBVIE INC - COLLABORATION TO DEVELOP MASKED T-CELL ENGAGERS
ABBVIE INC - XILIO TO RECEIVE $52 MILLION UPFRONT, ELIGIBLE FOR UP TO $2.1 BILLION
Source text: ID:nPn9Fv6m9a
Further company coverage: ABBV.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.